Danaher

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Danaher 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DHR

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. 

CEO
Rainer M. Blair
CEORainer M. Blair
Employees
60,000
Employees60,000
Headquarters
Washington, District of Columbia
HeadquartersWashington, District of Columbia
Founded
1984
Founded1984
Employees
60,000
Employees60,000

DHR Key Statistics

Market cap
138.47B
Market cap138.47B
Price-Earnings ratio
38.74
Price-Earnings ratio38.74
Dividend yield
0.70%
Dividend yield0.70%
Average volume
3.63M
Average volume3.63M
High today
$200.39
High today$200.39
Low today
$193.43
Low today$193.43
Open price
$197.00
Open price$197.00
Volume
2.89M
Volume2.89M
52 Week high
$242.80
52 Week high$242.80
52 Week low
$180.03
52 Week low$180.03

Stock Snapshot

Danaher(DHR) stock is priced at $195.67, giving the company a market capitalization of 138.47B. It carries a P/E multiple of 38.74 and pays a dividend yield of 69.6%.

During the trading session on 2026-04-21, Danaher(DHR) shares reached a daily high of $200.39 and a low of $193.43. At a current price of $195.67, the stock is +1.2% higher than the low and still -2.4% under the high.

Trading volume for Danaher(DHR) stock has reached 2.89M, versus its average volume of 3.63M.

Over the past 52 weeks, Danaher(DHR) stock has traded between a high of $242.80 and a low of $180.03.

Over the past 52 weeks, Danaher(DHR) stock has traded between a high of $242.80 and a low of $180.03.

DHR News

The Motley Fool 2h
Danaher Q1 2026 Earnings Call Transcript

Image source: The Motley Fool. Tuesday, April 21, 2026 at 8 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Rainer Blair Executive Vice Presi...

Danaher Q1 2026 Earnings Call Transcript
Nasdaq 2h
Danaher Corp. May Be the Smartest Bet in Biotech Right Now

Key Points After a four-year downturn, early signs in 2026 suggest biotech funding is stabilizing. Danaher is guiding for 3%–6% revenue growth, assuming a gra...

Danaher Corp. May Be the Smartest Bet in Biotech Right Now
The Wall Street Journal 4h
Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains

Danaher boosted the upper end of its full-year earnings guidance, following a first-quarter earnings beat. Company Image Danaher boosted the upper end of its f...

Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains

Analyst ratings

89%

of 27 ratings
Buy
88.9%
Hold
11.1%
Sell
0%

More DHR News

Nasdaq 4h
Danaher Q1 Earnings Beat Estimates

Danaher (DHR) came out with quarterly earnings of $2.06 per share, beating the Zacks Consensus Estimate of $1.95 per share. This compares to earnings of $1.88 p...

Danaher Q1 Earnings Beat Estimates
Nasdaq 4h
Danaher Increases 2026 Adj. Earnings Guidance

(RTTNews) - Danaher (DHR) increased full year adjusted diluted net earnings per common share guidance to a range of $8.35 to $8.55 from previous guidance of $8....

Danaher Increases 2026 Adj. Earnings Guidance
Nasdaq 5h
Danaher Corp. Profit Advances In Q1

(RTTNews) - Danaher Corp. (DHR) revealed earnings for its first quarter that Increases, from last year The company's bottom line came in at $1.029 billion, or...

Danaher Corp. Profit Advances In Q1
TipRanks 4d
Danaher Establishes New $5 Billion Revolving Credit Facility

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 4d
Danaher price target lowered to $249 from $251 at Baird

Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Danaher (DHR) to $249 from $251 and keeps an Outperform rating on the shares. The firm...

Simply Wall St 6d
Assessing Danaher Valuation After New Access MeMed BV Diagnostic Approval

Advertisement Access MeMed BV approval puts Danaher’s diagnostics in focus Beckman Coulter Diagnostics, part of Danaher (DHR), has received CE 2797 mark appro...

Assessing Danaher Valuation After New Access MeMed BV Diagnostic Approval

People also own

Based on the portfolios of people who own DHR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.